Trial report in Pediatric diabetes, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
13 authors.
Taylor M TrioloThe Barbara Davis Center for Diabetes University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0003-4796-6542
Laura M JacobsenDivision of Pediatric Endocrinology University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-5144-7836
David CuthbertsonHealth Informatics Institute University of South Florida, Tampa, Florida, USA.ORCID 0000-0002-3785-9834
Emily K SimsDepartment of Pediatrics Division of Pediatric Endocrinology and Diabetology Indiana University, Indianapolis, Indiana, USA.ORCID 0000-0002-4393-954X
Heba M IsmailDepartment of Pediatrics Division of Pediatric Endocrinology and Diabetology Indiana University, Indianapolis, Indiana, USA.ORCID 0000-0003-0102-0030
Maria J RedondoSection of Diabetes and Endocrinology Texas Children's Hospital Baylor College of Medicine, Houston, Texas, USA.ORCID 0000-0001-5871-4645
Markus LundgrenUnit for Pediatric Endocrinology Department of Clinical Sciences Malmö Lund University, Malmö, Sweden.ORCID 0000-0001-6394-7689
Linda A DiMeglioDepartment of Pediatrics Division of Pediatric Endocrinology and Diabetology Indiana University, Indianapolis, Indiana, USA.ORCID 0000-0002-8033-6078
Peter A GottliebThe Barbara Davis Center for Diabetes University of Colorado Anschutz Medical Campus, Aurora, Colorado, USA.ORCID 0000-0002-7601-8536
Mark A AtkinsonDepartment of Pathology Immunology and Laboratory Medicine University of Florida, Gainesville, Florida, USA.ORCID 0000-0001-8489-4782
Jeffrey P KrischerHealth Informatics Institute University of South Florida, Tampa, Florida, USA.ORCID 0000-0003-4526-888X
Desmond A SchatzDivision of Pediatric Endocrinology University of Florida, Gainesville, Florida, USA.ORCID 0000-0002-1044-5762
Jay M SosenkoDivision of Endocrinology University of Miami, Miami, Florida, USA.ORCID 0000-0002-7204-8367
Funding
Data Coordinating Center for Type 1 Diabetes TrialNet (UC4)USF: TrialNet UC4-3UC4DK117009 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2017 to 2019
$49.6M
NIDDK Type 1 Diabetes TrialNet Data Coordinating CenterUC4DK106993 · NIDDK · UNIVERSITY OF SOUTH FLORIDA · PI KRISCHER, JEFFREY P · 2015 to 2015
$36.6M
Type 1 Diabetes TrialNet Clinical Network HubU01DK103282 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI CARLA J GREENBAUM, KURT J GRIFFIN · 2014 to 2026
$14.2M
Northwest Clinical Center for Type 1 Diabetes - TrialNetU01DK061034 · NIDDK · BENAROYA RESEARCH INST AT VIRGINIA MASON · PI GREENBAUM, CARLA J · 2001 to 2018
$10.3M
Type I Diabetes Trialnet at StsnfordU01DK061042 · NIDDK · STANFORD UNIVERSITY · PI WILSON, DARRELL M · 2001 to 2018
$8.5M
UCSF Trialnet: A Phase II Trial of Imatimib in New Onset Type I DiabetesU01DK061010 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI GITELMAN, STEPHEN E · 2001 to 2018
$8.1M
Type 1 Diabetes-A Proposal for Prevention & InterventionU01DK085476 · NIDDK · UNIVERSITY OF MINNESOTA · PI MORAN, ANTOINETTE M. · 2009 to 2018
$7.1M
Prediction and Prevention of Type I DiabetesU01DK061058 · NIDDK · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI BECKER, DOROTHY J · 2001 to 2018
$6.5M
TrialNet: University of Florida Clinical Center and NetworkU01DK085461 · NIDDK · UNIVERSITY OF FLORIDA · PI HALLER, MICHAEL JAMES · 2009 to 2018
$5.9M
TrialNet: Diabetes Type 1 PreventionU01DK085509 · NIDDK · UNIVERSITY OF COLORADO DENVER · PI GOTTLIEB, PETER A · 2009 to 2018
$5.8M
Type 1 Diabetes TrialNet Clinical Center: Effects of Alefacept in New Onset T1DU01DK085499 · NIDDK · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI BAIDAL, DAVID · 2009 to 2018
$4.9M
Vanderbilt University: Clinical Center Application, Type 1 Diabetes TrialNetU01DK085465 · NIDDK · VANDERBILT UNIVERSITY MEDICAL CENTER · PI RUSSELL, WILLIAM E · 2009 to 2018
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Effect of Oral Insulin on Early Combined Glucose and C-Peptide Endpoints in Individuals at High-Risk for Type 1 Diabetes. · full record | OpenQuestion